華映科技(000536.SZ):公司股東受讓渤海信託受益權
格隆匯12月24日丨華映科技(000536.SZ)公佈,公司收到股東福建省電子信息(集團)有限責任公司(“福建電子信息集團”)通知,福建電子信息集團於2019年12月23日分別與華融證券(代表“華融股票寶34號集合資產管理計劃”)及福建山田實業發展有限公司(“山田實業”)簽訂《信託受益權轉讓協議》,受讓華融證券與山田實業在《渤海信託·華映光電集合資金信託合同》(合同編號包括bitc2016(t)-10803號-1號、bitc2016(t)-10803號-2號及bitc2016(t)-10803號-3號)項下享有的全部信託受益權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.